BRUCE A YANKNER, M.D.
Neurology in Boston, MA

6440387, Aug 27, 2002

Jan 28, 1999

09/239387

Bruce A. Yankner - West Newton MA
Philip Nadeau - Boston MA

Childrens Medical Center Corporation - Boston MA

A61K 4900

424 91, 514182

Blood cholesterol levels are correlated with production of amyloid protein (A), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A. For example, individuals with Apo E4 and high cholesterol, defined as a blood cholesterol level of greater than 200 mg/dl, post menopausal women with high cholesterol levels—especially those who are not taking estrogen, or individuals which high blood cholesterol levels who are not obese are all at risk of developing AD if blood cholesterol levels are not decreased.

2002018, Dec 5, 2002

Jul 14, 2002

10/198331

Bruce Yankner - West Newton MA, US
Philip Nadeau - Boston MA, US

Children's Medical Center Corporation

A61K031/401, A61K031/365, A61K031/225

514/423000, 514/460000, 514/548000

Blood cholesterol levels are correlated with production of amyloid protein (A), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels, Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A. For example, individuals with Apo E4 and high cholesterol, defined as a blood cholesterol level of greater than 200 mg/dl, post menopausal women with high cholesterol levels—especially those who are not taking estrogen, or individuals which high blood cholesterol levels who are not obese are all at risk of developing AD if blood cholesterol levels are not decreased

2002012, Aug 29, 2002

Feb 28, 2002

10/086398

Bruce Yankner - West Newton MA, US
Philip Nadeau - Boston MA, US

Children's Medical Center Corporation

A61K031/401, A61K031/366

514/423000, 514/460000, 514/547000

Blood cholesterol levels are correlated with production of amyloid protein (A), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A. For example, individuals with Apo E4 and high cholesterol, defined as a blood cholesterol level of greater than 200 mg/dl, post menopausal women with high cholesterol levels—especially those who are not taking estrogen, or individuals which high blood cholesterol levels who are not obese are all at risk of developing AD if blood cholesterol levels are not decreased.

2006002, Feb 2, 2006

Sep 22, 2005

11/232844

Bruce Yankner - Boston MA, US
Philip Nadeau - Boston MA, US

A61K 31/401, A61K 31/366, A61K 31/225

514423000, 514460000, 514548000

Blood cholesterol levels are correlated with production of amyloid β protein (Aβ), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of Aβ, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of Aβ. For example, individuals with Apo E4 and high cholesterol, defined as a blood cholesterol level of greater than 200 mg/dl, post menopausal women with high cholesterol levels—especially those who are not taking estrogen, or individuals which high blood cholesterol levels who are not obese are all at risk of developing AD if blood cholesterol levels are not decreased.

6080778, Jun 27, 2000

Mar 23, 1998

9/046235

Bruce A. Yankner - West Newton MA
Philip Nadeau - Boston MA

Children's Medical Center Corporation - Boston MA

A61K 3135, A61K 31235

514451

Blood cholesterol levels are correlated with production of amyloid. beta. protein (A. beta. ), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A. beta. , thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A. beta. For example, individuals with Apo E4 and high cholesterol, defined as a blood cholesterol level of greater than 200 mg/dl, post menopausal women with high cholesterol levels--especially those who are not taking estrogen, or individuals which high blood cholesterol levels who are not obese are all at risk of developing AD if blood cholesterol levels are not decreased.

5876948, Mar 2, 1999

Jul 29, 1991

7/737371

Bruce A. Yankner - Boston MA

The Children's Medical Center Corporation - Boston MA

G01N 3353

435 721

Method for treatment of a disease in a patient characterized by accumulation of. beta. -amyloid. The method includes identifying a patient potentially suffering from such a disease and contacting a neuron of the patient with a therapeutically effective amount of a tachykinin agonist. Methods for screening for compounds useful for treating such a disease are also disclosed.

5137873, Aug 11, 1992

Jul 27, 1990

7/559173

Bruce A. Yankner - Boston MA

The Children's Medical Center Corporation - Boston MA

A61K 3742, A61K 3702, C07K 706, C07K 722

514 15

Method for treatment of a disease in a patient characterized by accumulation of. beta. -amyloid. The method includes identifying a patient potentially suffering from such a disease and contacting a neuron of the patient with a therapeutically effective amount of a tachykinin agonist such as substance P. Methods for screening for compounds useful for treating such a disease are also disclosed.

2008027, Nov 6, 2008

Jun 9, 2005

11/629223

Bruce Yankner - Newton MA, US
Tao Lu - Brookline MA, US

C12Q 1/68

435 6

The invention relates to gene regulation in ageing, and age-related cognitive decline. The invention, in particular relates to methods for screening a subject for a propensity to develop diseases associated with oxidative stress, and for age-related conditions, by examining the up-regulation and/or down-regulation of at least one gene associated within the central nervous system.